

The Future and Challenges of the Manufacturing of Antibody-Drug Conjugates

*Kern H. Chang, Ph.D.,
Chief Technical Officer at Lotte Biologics*

In 2019, Daiichi Sankyo and AstraZeneca formed a partnership to globally develop and market Enhertu, which showcased the effectiveness of the Low Potent High DAR strategy. Enhertu garnered FDA approval in the same year for treating advanced breast cancer. Subsequently, in 2023, it received another significant approval for a distinct type of breast cancer characterized by low HER2 expression. Following this milestone, annual sales of Enhertu surged from \$1.24 billion to \$2.56 billion.

Undoubtedly, ADCs represent a realm of immense potential. Reflecting on the historical trajectory of ADCs prompts us to ponder their future. What might lay ahead for ADC technology? What direction is it poised to take? In this talk, we aim to explore the future landscape and the manufacturing challenges associated with ADCs.